Incidence and mortality of neurofibromatosis: A total population study in Finland

Journal of Investigative Dermatology

Volumn 135, Issue 3, 2015, Pages 904-906

  Uusitalo, Elina ^a   Leppävirta, Jussi ^b   Koffert, Anna ^b   Suominen, Sakari ^b,c   Vahtera, Jussi ^b   Vahlberg, Tero ^a   Pöyhönen, Minna ^d   Peltonen, Juha ^a   Peltonen, Sirkku ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AUTOSOMAL DOMINANT INHERITANCE; CARDIOVASCULAR DISEASE; CHROMOSOME 22; CLINICAL FEATURE; DEMENTIA; FINLAND; GENE MUTATION; HUMAN; INCIDENCE; LETTER; LIFE EXPECTANCY; LIFESPAN; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NEUROFIBROMATOSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; CARDIOVASCULAR MORTALITY; CONSENSUS DEVELOPMENT; FEMALE; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS TYPE 2; PREVALENCE; STANDARDIZED MORTALITY RATIO; ADULT; AGED; COMPARATIVE STUDY; MIDDLE AGED; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FINLAND; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; SEX FACTORS; SURVIVAL RATE;

EID: 84922664696     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.465     Document Type: Letter

References (16)

1. Antinheimo J, Sankila R, Carpén O et al. (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-Associated meningiomas and schwannomas. Neurology 54:71-6
2. Duong TA, Sbidian E, Valeyrie-Allanore L et al. (2011) Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis 6:18
3. Evans DG, Howard E, Giblin C et al. (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327-32
4. Evans DG, Huson SM, Donnai D et al. (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603-18
5. Evans DG, O'Hara C, Wilding A et al. (2011) Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet 19:1187-91
6. Gissler M, Haukka J (2004) Finnish health and social welfare registers in epidemiological research. Norsk Epidemiologi 14:113-20
7. Huson S, Compston D, Clark P et al. (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 26:704-11
8. Jouhilahti EM, Peltonen S, Heape AM et al. (2011) The pathoetiology of neurofibromatosis 1. Am J Pathol 178:1932-9
9. Lammert M, Friedman J, Kluwe L et al. (2005) Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 141:71-4
10. Poyhonen M, Kytola S, Leisti J (2000) Epidemiology of neurofibromatosis type 1 (NF1) in northern Finland. J Med Genet 37:632-6
11. Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68:1110-8
12. Rouleau GA, Merel P, Lutchman M et al. (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363:515-21
13. Stumpf D, Alksne J, Annegers J et al. (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Archives of Neurology 45:575-8
14. S-rensen SA, Mulvihill JJ, Nielsen A (1986) Long-Term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med 314:1010-5
15. Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a populationbased cancer registry. Experience in Finland. Acta Oncol 33:365-9
16. Zo ller M, Rembeck B, Akesson HO et al. (1995) Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm Venereol 75:136-40